Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ANEB Anebulo Pharmaceuticals
2.660-0.390-12.79%
Close
01/27 16:00 ET
2.6600.0000.00%
Post Mkt Price 01/27 19:57 ET
High
3.030
Open
3.030
Turnover
77.89K
Low
2.500
Pre Close
3.050
Volume
28.97K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Anebulo Pharmaceuticals Completes Dosing in ANEB-001 Study for ACI Treatment
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Large Increase in Short Interest
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totall
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.Axcella Heal
Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
Gainers Summit Therapeutics Inc. (NASDAQ:SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific
Anebulo Pharmaceuticals Q1 EPS $(0.11) Down From $(0.07) YoY
Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.11) per share. This is a 57.14 percent decrease over losses of $(0.07) per share from the same period last year.
Anebulo Pharmaceuticals 1Q Loss/Shr 11c >ANEB
Anebulo Pharmaceuticals 1Q Loss $2.61M >ANEB
Anebulo Pharmaceuticals Stockholders May Sell Up to 4.53M Shrs
Anebulo Pharmaceuticals Announces Appointment of Nat Calloway to Board of Directors
Anebulo Pharmaceuticals (NASDAQ:ANEB) Trading Up 3.4%
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) shares rose 3.4% during trading on Monday . The stock traded as high as $1.86 and last traded at $1.85. Approximately 3,706 shares were traded
Company Overview
More
Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. The firm’s product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.
CEO： Mr. Simon Allen, M.B.A.
Market： NASDAQ
Listing Date： 05/07/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet